A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind,
parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with
schizophrenia having an acute exacerbation of psychosis.